NCT03761407 - A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2004

Primary Completion Date

July 26, 2005

Study Completion Date

July 26, 2005

Conditions

Acute Pain

Interventions

DRUG

100 mg GRT0151Y

100 mg capsule (1 x 100 mg capsule)

DRUG

125 mg GRT0151Y

125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)

DRUG

150 mg GRT0151Y

150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)

DRUG

225 mg GRT0151Y

Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)

DRUG

Matching placebo

Matching placebo capsules using the same dosing regimen as defined in the treatment groups.

Trial Locations (1)

ASTER, Paris